Aragen to operationalize state-of-the-art formulation manufacturing plant in Hyderabad, India

Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO), today announced that it will commission its state-of-the-art formulation manufacturing facility at Mallapur Campus, Hyderabad, India by January 2023. The new 12,000 square foot facility will enhance the company’s ability to provide clinical supplies to customers through its integrated development and manufacturing of drug substances and drug products.

The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting – with expansion plans already in place to add nano-milling and hot extrusion capabilities.

These new capabilities at the Mallapur campus will further enhance Aragen’s New Chemical Entity (NCE) early development offerings, providing customers with the ability to discover and develop drugs from a co-located facility. It will provide greater flexibility to meet customers’ clinical supply needs in multiple dosage forms, with flexible processing technologies and batch sizes ranging from 1,000 units to 100,000 units.

1. Facility will enhance Aragen’s clinical formulation development and manufacturing offerings

2.Will offer both integrated and stand-alone formulation solutions to partners

Speaking on development, Manni Kantipudi, Managing Director, Aragen Life Sciences, said, “Aragen invests in capacity expansion, capacity expansion and expanding its geographic footprint to meet the needs of the global biopharmaceutical industry. We understand that our clients rely on our expertise, track record and solution offerings. With this facility, we will consolidate our pharmaceutical product development solutions offerings and strengthen our position as a one-stop-shop for all their needs – turning ideas into solutions for better health.

Once completed and fully operational, Aragan will support its customers with cGMP manufacturing and Phase I-III clinical supplies of tablets, capsules, liquids, semi-solids and films. The facility will offer purpose-built manufacturing suites to support wet granulation, roller compaction, fluidized bed coating, spray drying, micronization, nano-grinding, compression, capsules, coating and packaging.

Ramesh Subramanian, Commercial Director, Arabian Life Sciencessaid, “The formulation manufacturing facility in Hyderabad is an important development for us. The new capability will allow us to respond to our customers’ growing interest in integrated development solutions. It also aligns well with our stated vision of becoming the “R&D partner of choice” for our customers. With this pharmaceuticals facility and our recent acquisition of Intox – to provide safety assessment services – we can now help our Hit partners to Clinical Proof of Concept-Phase IIB, accelerating their journey to impact on patients.